In this article, we discuss recent advances in the management of CKD associated with T2D, providing an overview of the evidence for cardiorenal protection through the use of sodium glucose co-transporter type 2 (SGLT-2) inhibitors and the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Figure 1). Here, SLC5A2 is linked to type 2 diabetes mellitus.